Adding bevacizumab to embolization for chronic subdural hematoma
Treatments studied
Part of Brain & nervous system, Heart & circulation, Injuries & trauma clinical trials.
This trial tests adding a drug called bevacizumab (given directly into the blood vessels of the brain) to the standard procedure of middle meningeal artery embolization for a chronic subdural hematoma (a slow blood clot on the brain). The goal is to see if the combination helps reduce the chance of the clot returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need to be between 18 and 85 years old.
- You must be scheduled to have a middle meningeal artery embolization (a procedure that helps stop bleeding around the brain) as part of your standard care, and you should not be planning to have surgery to remove the blood clot at the same time.
- You have a chronic subdural hematoma (a slowly forming blood clot on the brain's surface) with a volume between 20 and 100 milliliters, and the pressure effect on the brain is not too severe (estimated by CT scans).
- You should be able to care for yourself (no major disability) and not have other serious neurological problems.
- You must not have had certain types of brain surgery (like removing the outer membrane of the brain) or a prior embolization for this same clot.
- You need to have normal kidney function, no uncontrolled high blood pressure, and no allergy to the study drug (bevacizumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a procedure called middle-meningeal-artery embolization, which blocks the blood supply to a chronic subdural hematoma (a slow-growing blood collection around the brain). It compares outcomes in people with one-sided versus both-sided bleeds, and aims to see if this less invasive treatment can help reduce the need for surgery or improve recovery.
This trial tests a minimally invasive procedure to treat chronic subdural hematoma (a slow bleed on the brain). It aims to stop the bleeding and reduce the risk of needing surgery.
This trial compares a newer, less invasive treatment (embolization) with traditional surgery to treat chronic subdural hematoma (a slow bleed on the brain). It aims to see which approach works better and has fewer side effects.
This trial tests a procedure called middle meningeal artery embolization, which aims to stop the bleeding and reduce the fluid buildup from a chronic subdural hematoma. It may be an option for patients who have a hematoma at least 10mm thick and one or more risk factors such as older age, blood thinners, diabetes, or certain scan features.
This trial studies whether an add-on, minimally invasive procedure works better than standard care for a specific brain blood-vessel problem (CSH) that is larger than 10 mm. It may help reduce symptoms or prevent worsening, if you meet the size and location requirements.
This trial compares different materials used during a procedure to treat chronic subdural hematoma, a collection of old blood on the brain's surface. The goal is to see which material works best to prevent the blood from coming back.
Hear when a new Chronic Subdural Hematoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.